This is a prospective, multicenter study conducted within the Chinese Children's Cancer Group (CCCG). The study aims to evaluate whether the addition of three novel agents, dasatinib, venetoclax and homoharringtonine, can improve the minimal residual disease (MRD)-negative remission rate, enhance event-free survival (EFS), and reduce the cumulative incidence of relapse (CIR) in pediatric patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL).
Age older than 1 month to younger than 18 years.
Diagnosis of acute lymphoblastic leukemia by bone marrow morphology.
Diagnosis of T-ALL by immunophenotyping.
B-ALL
AML
Acute leukemias of ambiguous lineage diagnosed according to WHO or EGIL criteria.
ALL evolved from chronic myeloid leukemia (CML).
Institute of Hematology & Blood Diseases Hospital, China
Lead sponsor